A prospective study of minimal residual disease in urological cancers using circulating tumour DNA

BJU InternationalEarly View Research Letter A prospective study of minimal residual disease in urological cancers using circulating tumour DNA Arnav Srivastava, Corresponding Author Arnav Srivastava [email protected] [email protected] orcid.org/0000-0002-9772-1415 Department of Urology, Michigan Medicine, Ann Arbor, MI, USA Correspondence: Arnav Srivastava, 2800 Plymouth Road, Building 16, Ann Arbor, MI 48109, USA. e-mail: [email protected] and [email protected]Search for more papers by this authorDerrian Cooley, Derrian Cooley Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorSteven M. Monda, Steven M. Monda orcid.org/0000-0002-8548-8193 Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorUlka N. Vaishampayan, Ulka N. Vaishampayan Department of Internal Medicine, Hematology/Oncology Division, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorSamuel D. Kaffenberger, Samuel D. Kaffenberger Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorLindsey A. Herrel, Lindsey A. Herrel orcid.org/0000-0003-0221-0784 Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorJeffrey S. Montgomery, Jeffrey S. Montgomery Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorKhaled Hafez, Khaled Hafez Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorAaron M. Udager, Aaron M. Udager orcid.org/0000-0002-8254-5404 Department of Pathology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorZachery R. Reichert, Zachery R. Reichert orcid.org/0000-0003-0356-8796 Department of Internal Medicine, Hematology/Oncology Division, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorD. Bryan Johnson, D. Bryan Johnson Strata Oncology, Ann Arbor, MI, USASearch for more papers by this authorDaniel R. Rhodes, Daniel R. Rhodes Strata Oncology, Ann Arbor, MI, USASearch for more papers by this authorScott A. Tomlins, Scott A. Tomlins Strata Oncology, Ann Arbor, MI, USASearch for more papers by this authorTodd M. Morgan, Todd M. Morgan Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this author Arnav Srivastava, Corresponding Author Arnav Srivastava [email protected] [email protected] orcid.org/0000-0002-9772-1415 Department of Urology, Michigan Medicine, Ann Arbor, MI, USA Correspondence: Arnav Srivastava, 2800 Plymouth Road, Building 16, Ann Arbor, MI 48109, USA. e-mail: [email protected] and [email protected]Search for more papers by this authorDerrian Cooley, Derrian Cooley Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorSteven M. Monda, Steven M. Monda orcid.org/0000-0002-8548-8193 Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorUlka N. Vaishampayan, Ulka N. Vaishampayan Department of Internal Medicine, Hematology/Oncology Division, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorSamuel D. Kaffenberger, Samuel D. Kaffenberger Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorLindsey A. Herrel, Lindsey A. Herrel orcid.org/0000-0003-0221-0784 Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorJeffrey S. Montgomery, Jeffrey S. Montgomery Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorKhaled Hafez, Khaled Hafez Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorAaron M. Udager, Aaron M. Udager orcid.org/0000-0002-8254-5404 Department of Pathology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorZachery R. Reichert, Zachery R. Reichert orcid.org/0000-0003-0356-8796 Department of Internal Medicine, Hematology/Oncology Division, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this authorD. Bryan Johnson, D. Bryan Johnson Strata Oncology, Ann Arbor, MI, USASearch for more papers by this authorDaniel R. Rhodes, Daniel R. Rhodes Strata Oncology, Ann Arbor, MI, USASearch for more papers by this authorScott A. Tomlins, Scott A. Tomlins Strata Oncology, Ann Arbor, MI, USASearch for more papers by this authorTodd M. Morgan, Todd M. Morgan Department of Urology, Michigan Medicine, Ann Arbor, MI, USASearch for more papers by this author First published: 13 August 2025 https://doi.org/10.1111/bju.16890Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookxLinkedInRedditWechatBluesky No abstract is available for this article. References 1Brown JR, Sonpavde GP, Calaway A, Barata PC. Circulating tumor DNA to assess minimal residual disease: versatile, but how valuable? Eur Urol 2024; 86: 312–314 10.1016/j.eururo.2024.06.002 CAS PubMed Google Scholar 2Correa AF, Kalashnikova E, Wu HT et al. Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma. Oncologist 2024; 29: 887–893 10.1093/oncolo/oyae180 PubMed Web of Science® Google Scholar 3Ben-David R, Tillu N, Cumarasamy S et al. Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy. European Urology Oncology 2024; 7: 1105–1112 10.1016/j.euo.2024.03.002 PubMed Web of Science® Google Scholar 4Wang Y, Li L, Cohen JD et al. Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer. JAMA Oncol 2019; 5: 1118–1123 10.1001/jamaoncol.2019.0512 PubMed Web of Science® Google Scholar 5Powles T, Assaf ZJ, Degaonkar V et al. Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma. Eur Urol 2024; 85: 114–122 10.1016/j.eururo.2023.06.007 CAS PubMed Web of Science® Google Scholar 6Tomlins SA, Hovelson DH, Harms P et al. Development and validation of StrataNGS, a multiplex PCR, semiconductor sequencing-based comprehensive genomic profiling test. J Mol Diagn 2021; 23: 1515–1533 10.1016/j.jmoldx.2021.08.005 CAS PubMed Web of Science® Google Scholar 7Huelster HL, Gould B, Schiftan EA et al. Novel use of circulating tumor DNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma. Eur Urol 2024; 85: 283–292 10.1016/j.eururo.2023.09.017 CAS PubMed Web of Science® Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation